Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Guardant Health Inc. Common Stock (GH) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Guardant Health Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Guardant Health Inc. Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.18 (market cap $763.64M), while Guardant Health Inc. Common Stock trades at $168.62 (market cap $22.22B). The key difference: Guardant Health Inc. Common Stock is far larger — about 29.1× Ginkgo Bioworks Holdings Inc's market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Guardant Health Inc. Common Stock for 0 Days on average.

DNAGH
Market Cap
$763.64M$22.22B
Volume
3,204,1771,589,453
Sector
HealthHealth
52-Week High
$15.83$187.22
52-Week Low
$5.48$61.73
Typical Hold Time
7 Days0 Days
Enterprise Value
$865.59M$22.86B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Guardant Health Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
53% Buy47% Sell
Avg holding period · 7 Days
GH
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About Guardant Health Inc. Common Stock

Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.

Read more on GH →